Skip to main content
S&P 5007,616.46+0.41%DOW52,090.800.00%NASDAQ26,184.39+0.78%BTC$75,720.00-0.87%ETH$2,392.07-1.44%GOLD$4,389.60+1.31%OIL$102.35-3.29%
Smart Investors Daily
CL

NASDAQ · CLNN

Clene Inc.

Healthcare · Biotechnology

$4.02

Up+$0.09 (+2.24%)

Updated Sep 16, 2026, 3:33 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
64.85M
P/E ratio
-2.23
Dividend yield
0.00%
52-week range
$3.25 – $8.67
Volume
479.09K
Avg. volume
192.2K

Price performance

CLNN price history

1M range · 20 trading sessions · Daily adjusted prices

CLNN closed at $4.02 after 20 trading sessions, down 1.71% for the selected period.

Last close
$4.02
Period change
-1.71%
Period low
$3.28
Period high
$4.65
Daily close
View OHLC price history
CLNN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$3.25$4.18$3.25$4.02479.09K
Sep 14, 2026$3.57$3.72$3.26$3.28140.86K
Sep 11, 2026$3.72$3.76$3.52$3.57124.97K
Sep 10, 2026$3.67$3.931$3.605$3.65113.16K
Sep 9, 2026$3.67$3.84$3.48$3.72159.33K
Sep 8, 2026$3.82$3.82$3.60$3.62252.78K
Sep 4, 2026$3.92$4.00$3.72$3.85122.56K
Sep 3, 2026$4.18$4.2172$3.75$3.995145.08K
Sep 2, 2026$4.10$4.28$3.88$4.16107.57K
Sep 1, 2026$4.22$4.42$4.02$4.105159.51K
Aug 31, 2026$4.31$4.3199$4.1135$4.2841.28K
Aug 28, 2026$4.43$4.7374$4.17$4.2359.66K
Aug 27, 2026$4.67$4.8022$4.40$4.4732.98K
Aug 26, 2026$4.43$4.745$4.26$4.6589.85K
Aug 25, 2026$4.47$4.58$4.20$4.44112.1K
Aug 24, 2026$4.31$4.53$4.24$4.43537.31K
Aug 21, 2026$4.40$4.41$4.1326$4.3228.89K
Aug 20, 2026$4.24$4.37$4.10$4.3723.08K
Aug 19, 2026$4.18$4.34$4.10$4.1949.34K
Aug 18, 2026$4.19$4.4687$4.08$4.0973.37K

Latest CLNN news

The latest Smart Investors Daily articles mentioning CLNN.

Stock researchCompany · Overview

CLNN research

Overview

Company profile and research snapshot.

Company profile

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$50.00
Implied upside
—
Analysts
—
CLNN recent ratings
DateFirmRatingTarget
May 4, 2026HC Wainwright & Co.Buy—
May 4, 2026D. Boral CapitalBuy—
Mar 13, 2026Canaccord GenuityBuy—
Mar 12, 2026D. Boral CapitalBuy—
Jan 9, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Clene to Present at Upcoming September Investor Conferences

SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference and host 1x1 investor meetings at both conferences. 2026 Cantor Global Healthcare ConferenceDate: September 9, 2026Time of Presentation: 9:10am ETLocation: New York, NYFormat: Presentation and 1x1 meetings1x1 Meetings: Please contact your Cantor representativeWe

globenewswire.com · Dec 9, 2025

Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream

MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 and 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth.

Yahoo · Dec 3, 2025

Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8’s potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By